focused on peripheral blood CD8+ T lymphocytes to identify potential predictors and indicated that the number of effector or memory CD8+ T lymphocytes (CCR7−CD45RA−) was reduced (184, 185), while exhausted tumour-reactive CD8+ T lymphocytes (TIGIT+ PD-1+) reached to a high level in hyperprogressive NSCLC patients (186). The gene discussed is CD8A; the disease is neoplasm.